ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PRAX Praxis Precision Medicines Inc

71.76
-5.12 (-6.66%)
16 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Praxis Precision Medicines Inc NASDAQ:PRAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.12 -6.66% 71.76 40.00 249.50 77.00 69.54 76.57 552,517 01:00:00

Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference

06/04/2023 2:00pm

GlobeNewswire Inc.


Praxis Precision Medicines (NASDAQ:PRAX)
Historical Stock Chart


From Nov 2022 to Nov 2024

Click Here for more Praxis Precision Medicines Charts.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 12:45 p.m. ET.

The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

About PraxisPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.

Investor Contact
Alex Kane
Praxis Precision Medicines
investors@praxismedicines.com
617-300-8481

Media Contact
Ian Stone
Canale Communications
Ian.stone@canalecomm.com
619-849-5388

1 Year Praxis Precision Medicines Chart

1 Year Praxis Precision Medicines Chart

1 Month Praxis Precision Medicines Chart

1 Month Praxis Precision Medicines Chart